SCHEMBL4099328

SCHEMBL4099328

CCCCCCCC/C=C\CCCCCCCCCCCC(=O)Oc1ccc(C=Cc2cc(OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)cc(OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
LMNA P02545 1/20 0.51
TTR P02766 1/20 0.51
TP53 P04637 1/20 0.51
CYP3A4 P08684 1/20 0.51
MAPT P10636 1/20 0.51
POLM Q9NP87 1/20 0.47
POLK Q9UBT6 1/20 0.47
POLL Q9UGP5 1/20 0.47
POLH Q9Y253 1/20 0.47
CNR1 P21554 2/20 0.46
RET P07949 1/20 0.46
TOP2A P11388 2/20 0.46
FFAR1 O14842 1/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2519160 1.00 KMT2A (0.51) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL2523313 0.98 KDM4E (0.49) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL2516512 0.94 ALB (0.46) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL4097832 0.94 ALB (0.46) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL4098725 0.94 MAPT (0.50) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL2516296 0.94 KMT2A (0.57) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL20581800 0.94 KMT2A (0.57) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL20581976 0.94 KMT2A (0.57) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL4096603 0.94 KMT2A (0.57) KMT2ASMN1; SMN2KDM4EMEN1LMNA
SCHEMBL4092148 0.94 KMT2A (0.57) KMT2ASMN1; SMN2KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9295621-B2 Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant ELC MANAGEMENT LLC (US) 2016-03-29 US disclosed
US-20090035240-A1 Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035237-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant ELC MANAGEMENT LLC 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035237-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant SMURF1, CUTA, SMURF2 KMT2A 1425/4885SMN1; SMN2 919/4885KDM4E 1074/4885
US-20090035240-A1 Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent SMARCC1, RARG, RARA KMT2A 1387/4885SMN1; SMN2 2191/4885KDM4E 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.